Icahn School of Medicine at Mount Sinai, United States of America.
Clin Imaging. 2021 Dec;80:19-25. doi: 10.1016/j.clinimag.2021.06.035. Epub 2021 Jun 30.
Partial breast irradiation (PBI) and ultra-hypofractionated whole breast irradiation (uWBI) are contemporary alternatives to conventional and standard hypofractionated whole breast irradiation (WBI), which shorten treatment from 3 to 6 weeks to 1-2 weeks for select patients. PBI and accelerated PBI (APBI) can be delivered with external beam radiation (3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT)), intraoperative radiation (IORT), or brachytherapy. These new radiation techniques offer the advantage of convenience and lower cost, which ultimately improves access to care. Globally, the COVID 19 pandemic has accelerated APBI/PBI and ultra-hypofractionated regimens into routine practice for carefully selected patients. Recent long-term data from randomized controlled trials (RCTs) have demonstrated these techniques are safe and effective in suitable patients demonstrating equivalent or improved local recurrence, acute/late toxicity, and cosmesis. PBI and APBI should be limited to low risk unifocal invasive ductal carcinoma and ductal carcinoma in situ with tumor size < 2 cm, clear margins (≥2 mm), ER+, and negative nodes. Based on the results from UK Fast-Forward and UK FAST ultra-hypofractionated breast radiation can be safely employed for early stage node negative patients, but is not yet considered an international standard of care. In this review, authors will appraise recent data for these shorter course radiation treatment regimens, as well as, considerations for breast radiologists including surveillance imaging and radiographic findings.
部分乳房照射(PBI)和超超分割全乳房照射(uWBI)是传统和标准超分割全乳房照射(WBI)的当代替代方案,将治疗时间从 3 至 6 周缩短至 1 至 2 周,适用于部分患者。PBI 和加速 PBI(APBI)可以通过外部束放射治疗(三维适形放射治疗(3D-CRT)或调强放射治疗(IMRT))、术中放射治疗(IORT)或近距离放射治疗来完成。这些新的放射技术具有方便和成本低的优势,最终可以提高获得护理的机会。在全球范围内,COVID-19 大流行加速了 APBI/PBI 和超超分割方案在精心挑选的患者中常规应用。最近来自随机对照试验(RCT)的长期数据表明,这些技术在合适的患者中是安全有效的,证明了局部复发、急性/迟发性毒性和美容效果相当或改善。PBI 和 APBI 应限于低风险单灶性浸润性导管癌和导管原位癌,肿瘤大小<2cm,切缘清晰(≥2mm),ER+,淋巴结阴性。基于英国 Fast-Forward 和 UK FAST 超超分割乳房放射治疗的结果,早期无淋巴结转移的患者可以安全地采用这种治疗,但尚未被认为是国际标准的护理方法。在这篇综述中,作者将评估这些较短疗程放射治疗方案的最新数据,以及乳房放射科医生的考虑因素,包括监测成像和影像学表现。